News

MolecularMatch Announces new SDK and Improved Drug Search

MolecularMatch Announces new SDK and Improved Drug Search

Houston – October 2, 2019 – MolecularMatch, a leading clinical informatics company providing Precision Medicine software solutions for oncology, announced the release of MMPower v4, the latest update to its Clinical Decision Support platform. This new release adds expanded therapeutic guidance and a new Software Developer’s Kit (SDK) to broaden language support and speed up time-to-market for software developers writing custom applications integrating with the MolecularMatch platform.

Key new features for MolecularMatch’s expanded therapeutic guidance include:

  • Expanded pharmacology details including mechanism of action, toxicity,
    contraindication and drug metabolism
  • Regional approval status now includes EMA and HCA in addition to FDA
  • Dosage options
  • Pricing specifics

About MolecularMatch

MolecularMatch, Inc. is a Houston, Texas based clinical informatics SaaS company established in 2014. The company was founded on the vision of using tumor molecular profiling and outcomes from previously-treated patients to provide the best personalized treatment for current patients. MolecularMatch delivers personalized, evidence-based therapeutic guidance and clinical trials matched to each patient. Customers include genetic labs, health information systems, biopharma, hospitals and cancer centers. Visit us at molecularmatch.com or follow us on Twitter or LinkedIn.

Scott L. Bender
MolecularMatch
+1-214-435-4498
sbender@molecularmatch.com

MolecularMatch Announces Issuance of US Patent for its Precision Medicine Service

MolecularMatch Announces Issuance of US Patent for its Precision Medicine Service

Houston – August 08, 2019 – MolecularMatch, a leading clinical informatics company providing Precision Medicine software solutions for oncology, announced today that the United States Patent and Trademark Office has issued US Patent 10,360,349 covering its Precision Medicine Service for use by hospitals, pharmaceutical companies, laboratories, health information systems and the broader clinical informatics industry.

This latest patent covers the foundational technology for therapeutic guidance and clinical trial matching in MolecularMatch’s MM-Power and MM-Portal products.

“The Precision Medicine Service patent covers the process of data acquisition, curation and validation of our industry leading clinico-biological knowledge platform. It includes a state-of-the-art search engine designed to rank clinical relevance to a patient’s medical profile, providing real-time search results of treatment options inclusive of clinical trials,” said Nick Tackes, CTO at MolecularMatch. “Furthermore, our patent covers our clinical trial enrollment technology which is designed to expedite what is often a protracted process.”

“This patent is an important component as we continue to build upon strategic and technological advancements for our clinical decision support solutions,” said Eric Pulaski, President at MolecularMatch.

About MolecularMatch

MolecularMatch, Inc. is a Houston, Texas based clinical informatics SaaS company established in 2014 out of MD Anderson Cancer Center. The company was founded on the vision of using tumor molecular profiling and outcomes from previously-treated patients to provide the best personalized treatment for current patients. MolecularMatch delivers personalized, evidence-based therapeutic guidance and clinical trials matched to each patient. Customers include genetic labs, health information systems, biopharma, hospitals and cancer centers. Visit us at molecularmatch.com or follow us on Twitter or LinkedIn.

MolecularMatch appoints Eric Pulaski as President

MolecularMatch appoints Eric Pulaski as President

Pulaski joins executive team to drive product strategy and revenue growth

Houston – June 24, 2019 – MolecularMatch, a leading clinical informatics company providing Precision Medicine software solutions for oncology, announced today that Eric Pulaski will serve as President for MolecularMatch.

Pulaski has over 30 years of experience across the technology and software sector. Pulaski was most recently the Founder and CEO of SmartVault Corporation, a leading SaaS provider in the online document management and secure portal space. He founded the company in 2007 and ultimately sold it to Reckon Ltd in 2016. He was the founder and CEO of BindView, where he grew that company into a leading, global Internet Security company with over $70M in revenues and 650 employees, and later sold to Symantec for over $200M. Pulaski also founded and served as CEO for several other tech companies, including RedFlag Software and Lightbulb Technology Partners.

As a serial entrepreneur, Eric’s specialties are developing and executing product strategy, building and retaining high-performing teams during high-growth and change, evangelism and communication, and managing shareholder and investor relationships.

“Eric’s experience as a seasoned entrepreneur, especially as it relates to software businesses, makes him the perfect choice in leading MolecularMatch through a very unique period for our company,” said James W. Welsh, MD, Founder at MolecularMatch. “I am confident he will spearhead strategic initiatives that will help us accelerate growth.”

Pulaski said: “MolecluarMatch is a visionary company with a vibrant culture at the forefront of innovation in the heart of the Texas Medical Center. I look forward to working closely with Jim and the leadership team to capitalize on the enormous market opportunities in front of us.”

About MolecularMatch

MolecularMatch, Inc. is a Houston, Texas based clinical informatics SaaS company founded in 2014 out of MD Anderson Cancer Center. The company was founded on the vision of using tumor molecular profiling, and outcomes from previously-treated patients, to provide the best personalized treatment for current patients. MolecularMatch delivers personalized, evidence-based therapeutic guidance and clinical trials matched to each patient. Customers include genetic labs, health information systems, biopharma, hospitals and cancer centers. Visit us at molecularmatch.com

Roche Launches First Two NAVIFY Clinical Decision Support Apps

Roche Launches First Two NAVIFY Clinical Decision Support Apps

Basel Switzerland – Roche (September 18, 2018) –

(RTTNews) – Swiss drug major Roche Group (RHHBY) announced Tuesday the launch of the first two NAVIFY clinical decision support apps: The NAVIFY Clinical Trial Match and NAVIFY Publication Search apps.

The two apps available on the NAVIFY Tumor Board facilitates oncology care teams access relevant clinical trial information and related publications more effectively.

NAVIFY Clinical Trial Match app identifies clinical trial options based on patient-specific attributes such as age, gender, biomarkers and various tumour information from 11 international registries.

NAVIFY Publication Search app mines publication sources globally for most recent clinically and therapeutically relevant literature.

The content of both apps is provided by MolecularMatch, Inc., a clinical informatics company with expertise in precision oncology, immunotherapy and bioinformatics.

According to the firm, the launch of these first two apps is the start of the NAVIFY apps ecosystem. More apps from Roche, partners and third parties will follow to expand the clinical decision support functionalities.

(RTTNews) – Swiss drug major Roche Group (RHHBY) announced Tuesday the launch of the first two NAVIFY clinical decision support apps: The NAVIFY Clinical Trial Match and NAVIFY Publication Search apps.

The two apps available on the NAVIFY Tumor Board facilitates oncology care teams access relevant clinical trial information and related publications more effectively.

NAVIFY Clinical Trial Match app identifies clinical trial options based on patient-specific attributes such as age, gender, biomarkers and various tumour information from 11 international registries.

NAVIFY Publication Search app mines publication sources globally for most recent clinically and therapeutically relevant literature.

The content of both apps is provided by MolecularMatch, Inc., a clinical informatics company with expertise in precision oncology, immunotherapy and bioinformatics.

According to the firm, the launch of these first two apps is the start of the NAVIFY apps ecosystem. More apps from Roche, partners and third parties will follow to expand the clinical decision support functionalities.

MolecularMatch Introduces MMPower Knowledge Base – Providing One of the Industry’s Most Dynamic Molecular Search Engines

MolecularMatch Introduces MMPower Knowledge Base – Providing One of the Industry’s Most Dynamic Molecular Search Engines

Houston, TX – TMC Innovation – Texas Medical Center (April 24, 2017) –

April 24, 2017 03:42 PM Eastern Daylight Time

April 24, 2017 03:42 PM Eastern Daylight Time HOUSTON–(BUSINESS WIRE)–MolecularMatch has announced their new knowledge platform, MMPower. The Platform covers over 400 million alterations with the ability to process whole exomes in seconds. The complexity of genetic molecular data, in any format, is converted quickly by MMPower into understandable and meaningful information.

“We started with some of the best oncology minds in the world from a variety of institutions to create an automated way for applying clinical intelligence at the point of care. MolecularMatch’s automated technology reads and acquires thousands of genomic data sets weekly allowing our partners to efficiently provide evidence-based recommendations. Through Natural Language Processing we can examine and create associations among the information faster than any human can while applying the learned technology through our proprietary algorithms,” says MolecularMatch CEO, Mr. Kevin Coker. The MMPower platform can be utilized via a RESTful API or through access to a variety of solutions that augment different sectors of the precision medicine landscape. Organizations can customize MolecularMatch solutions to validate their molecular data assumptions or develop their own applications. MMPower is the foundation of MolecularMatch’s growing suite of solutions including:

  • Customized Somatic Assay Panel Design
  • Virtual Tumor Board Support
  • Molecular Profile Analytics
  • An Interactive Physician Engagement Portal containing dynamic reports
  • Molecular Diagnostic Reporting and Variant Exploration for Pathology Labs
  • Evidence-based Decision Support and Integration with enterprise technology such as LIMs and EMRs.

The company’s mission is to improve the adoption and utility of genomics for improving patient care. MolecularMatch also offers a complimentary clinical trial search capability allowing physicians and patients to search local clinical trials in their locality. Based in the heart of the Texas Medical Center, MolecularMatch is a clinical informatics company founded by Dr. James Welsh in 2014 with licensed technology out of MD Anderson Cancer Center. It is a technology first company that extracts insights from complex molecular information for organizations seeking to advance the clinical utility of genomics. Customers that benefit from our technology include biopharmaceutical, life sciences, and commercial diagnostic laboratories. Visit us at www.MolecularMatch.com today.